Secretion responsive Hydrogels for Identification of Functional single T cells (SHIFT)
Secretion responsive Hydrogels for Identification of Functional single T cells (SHIFT)
批准号:
10272884
负责人:
Rebecca Schulman
金额:
$21.51万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-09-16 至 2024-08-31
关键词:
AddressAdoptedAdoptive Cell TransfersAntigen-Presenting CellsAntigensAspirate substanceBase SequenceBenchmarkingBiological AssayBloodCD3 AntigensCaliberCell SeparationCell SurvivalCell secretionCellsClinicalClustered Regularly Interspaced Short Palindromic RepeatsCommunitiesCytotoxic T-LymphocytesDNADNA SequenceDetectionDevelopmentEmulsionsEncapsulatedEngineeringFree WillGelGenerationsHumanHydrogelsImmuneImmunotherapyIn SituIndividualInterferonsInterventionInvestigationLabelMalignant NeoplasmsMeasurementMeasuresMediatingMethodsMicrofluidicsPatientsPeptidesPhenotypePopulationPositioning AttributeProcessProtocols documentationRapid screeningReactionRecombinantsRecoveryRecovery of FunctionResearchSignal TransductionSorting - Cell MovementSwellingT-LymphocyteTechniquesTechnologyTherapeuticTumor AntigensTumor EscapeVariantantigen-specific T cellsbasecancer cellcancer immunotherapycell injurycell killingclinical applicationcost effectivecytokineengineered T cellshigh throughput screeningimmune activationimprovedmigrationmultiple omicsneoplastic celloptimismparticlepersonalized immunotherapypolymerizationpopulation basedpreservationpreventprogramsresponsescreeningsmall moleculetherapeutic developmenttooltreatment responsetumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract
Adoptive cell therapy has the potential to circumvent cancer immune evasion by employing patient-derived,
tumor-specific cytotoxic T-cells to attack cancer. While promising responses of advanced cases to cancer
immunotherapy bolster the optimism surrounding these therapeutic strategies, interpatient variations in treatment
responses demand a new method to select highly effective tumor-specific cytotoxic T-cells for better and safe
immunotherapy.
We propose a high-throughput, single-cell level method for identifying and recovering highly functional T cells
that secrete tumor-killing signals in the presence of tumors. Our proposed technology builds on transformational
advances in the generation of droplet emulsions, secretomics, and new hydrogel-based sensing techniques we
recently developed. In this assay, tumor-killing T cells and cancer cells will be encapsulated in pairs in a uniformly
sized, secreted factor-sensitive hydrogel droplet using a microfluidic droplet generator. The resulting isolated
reaction compartments for each cell pair will prevent the mixing of T cells' multiple secreted factors and will
concentrate them to allow sensitive detection. The hydrogel will respond to a factor secreted by functional T cells
via a dramatic size change, allowing hydrogels with active T cells to be reliably isolated from the heterogeneous
mixture using a hydrodynamic size-based particle sorting mechanism. The sorted pairs will be individually
recovered using an aspiration pipette and the hydrogel shell dissolved without cell damage, allowing for the
recovery of functional individual T cells. We propose to use this high-throughput assay, capable of screening
millions of T cells, to identify tumor-responsive T cells and to recover them for downstream analysis or
proliferation. This assay is simple, sensitive, and versatile enough to be used by a wide research community or
eventually within clinical settings for isolating and profiling rare cells with target secretory phenotypes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金